title: Mycobacterium tuberculosis drug-resistance in previously treated patients in Ouagadougou, Burkina Faso.
abstract: BACKGROUND
  Tuberculosis drug-resistance becomes common in sub-Saharan Africa; however, very few data are available in Burkina Faso. The aim of this study is to assess the acquired resistance of Mycobacterium tuberculosis complex strains identified in TB patients to four first-line drugs in Ouagadougou.
  
  
  METHODS
  One hundred and ten (110) pulmonary tuberculosis patients with acid-fast bacilli-positive sputum and in situation of failure, relapse, or treatment abandonment were included in the study. Ninety six strains, including 92 (95.8%) M. tuberculosis and 4 (4.2%) M. africanum, were isolated from the sputum samples of these patients. Their drug susceptibility testing was performed using the proportion method. The first-line drugs tested were isoniazid (INH), streptomycin (STR), ethambutol (EMB), and rifampicin (RIF).
  
  
  RESULTS
  The overall drug-resistance rate of M. tuberculosis was 67.4% (n=60), including 3.4% to one drug, 18% to two, 10.1% to three, and 35.9% to four drugs. The resistance to INH, RIF, EMB, and STR were 67.4%, 51.7%, 50.6%, and 44.9%, respectively. Two strains of M. africanum were resistant to all drugs. Forty-six (51.7%) strains were multidrug-resistant (resistant to at least INH and RIF).
  
  
  CONCLUSIONS
  In previously treated patients, the level of resistance of M. tuberculosis complex to commonly used anti-tuberculosis drugs is very high in Ouagadougou. Our results showed that multidrug-resistant tuberculosis could be a public health problem in Burkina Faso.
authors.affiliation: University Hospital Centre Yalgado Ouedraogo, Ouagadougou 03, Burkina Faso. sangarel@hotmail.com
authors.forename: L
authors.initials: L
authors.lastname: Sangare
authors.forename: S
authors.initials: S
authors.lastname: Diande
authors.forename: S
authors.initials: S
authors.lastname: Kouanda
authors.forename: B I
authors.initials: BI
authors.lastname: Dingtoumda
authors.forename: A
authors.initials: A
authors.lastname: Mourfou
authors.forename: F
authors.initials: F
authors.lastname: Ouedraogo
authors.forename: I
authors.initials: I
authors.lastname: Sawadogo
authors.forename: B
authors.initials: B
authors.lastname: Nebie
authors.forename: A
authors.initials: A
authors.lastname: Gueye
authors.forename: L T
authors.initials: LT
authors.lastname: Sawadogo
authors.forename: A S
authors.initials: AS
authors.lastname: Traore
mesh_terms: D000293:Adolescent; D000328:Adult; D017677:Age Distribution; D000368:Aged; D000995:Antitubercular Agents / Q000627:therapeutic use*; D002050:Burkina Faso / Q000453:epidemiology; D003430:Cross-Sectional Studies; D024901:Drug Resistance, Multiple, Bacterial; D005260:Female; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D009169:Mycobacterium tuberculosis / Q000187:drug effects* / Q000302:isolation & purification; D015995:Prevalence; D013183:Sputum / Q000382:microbiology; D016896:Treatment Outcome; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy* / Q000453:epidemiology / Q000382:microbiology; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy* / Q000453:epidemiology / Q000382:microbiology; D055815:Young Adult
chemical_list: D000995:Antitubercular Agents